BioSight
Companies
PROKIDNEY CORP. logo

PROK

NASDAQWINSTON-SALEM, NC
PROKIDNEY CORP.

ProKidney Corp. is a clinical-stage biotech company developing renal autologous cell therapy, with rilparencel as its lead program, focused on kidney disease treatment. The company is pursuing cell-based therapeutic approaches and requires additional capital to advance clinical trials and seek regulatory approval for its product candidates. ProKidney operates in the rare disease and nephrology space, where it faces competition, clinical trial risks, and regulatory scrutiny related to cell therapy modalities.

Price history not yet available for PROK.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar